Citius Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CITIUS PHARMS
CITIUS PHARMS has one approved drug.
There is one US patent protecting CITIUS PHARMS drugs.
Summary for Citius Pharms
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Citius Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-002 | Jun 13, 2011 | DISCN | No | No | 8,440,170 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-003 | Mar 27, 2012 | DISCN | No | No | 8,440,170 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-001 | Jun 13, 2011 | DISCN | No | No | 8,440,170 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Citius Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-001 | Jun 13, 2011 | 6,149,938 | ⤷ Start Trial |
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-003 | Mar 27, 2012 | 6,149,938 | ⤷ Start Trial |
| Citius Pharms | SUPRENZA | phentermine hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 202088-002 | Jun 13, 2011 | 6,149,938 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CITIUS PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Orally Disintegrating Tablets | 37.5 mg | ➤ Subscribe | 2013-03-22 |
| ➤ Subscribe | Orally Disintegrating Tablets | 15 mg and 30 mg | ➤ Subscribe | 2012-10-19 |
International Patents for Citius Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2009098169 | ⤷ Start Trial |
| European Patent Office | 2254558 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Citius Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2317997 | 2190050-1 | Sweden | ⤷ Start Trial | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
